Today, I’m proud to share that Condor Software has closed a $24 million Series A funding round, led by Insight Partners, with participation from Felicis, 645 Ventures, Pamir Ventures, SNR Ventures, Prebys Ventures, and Bramalea Partners.
Every therapy that reaches a patient is a miracle of science and resilience without financial clarity. Most people involved in therapies focus on science. I focus on finance, and what happens when it breaks down.
Read More – V-Glass Raises $3M in Seed Funding
Earlier in my career, I worked alongside teams bringing treatments to patients who had run out of options. I watched what it meant to families (including my own), to clinicians, and to entire communities when a therapy worked. I was on the inside, building the accounting workflows the pharmaceutical industry uses to manage clinical trial finances. What I saw blew my mind: organizations managing billions in R&D spend on spreadsheets stitched together late at night. Critical decisions about which therapies move forward, made on data that was fragmented, manually reconciled, erroneous, and months out of date.
Good science was being crushed by broken financial infrastructure. This shouldn’t be the case, and I knew I couldn’t let this continue. So I founded Condor.
A lot has changed since I founded the company five years ago. Our team has grown. Our platform has matured into the first ever AI-powered financial intelligence layer purpose-built for life sciences. And some of the world’s most innovative biopharma organizations — like Acadia Pharmaceuticals, Alumis Therapeutics, BridgeBio Pharma, and Madrigal Pharmaceuticals — now rely on Condor to manage over $19 billion in R&D spend.
What hasn’t changed is our mission: to empower biopharma teams to see, predict, and control the cost of bringing life-changing therapies to patients. And our mission has never been more urgent.
AI is completely transforming human health, drug discovery, disease prevention, and the way we treat, cure, and care for people. But here’s the uncomfortable truth nobody’s talking about: the future everyone’s envisioning can’t actually happen yet. Not because the science isn’t ready. Not because the data isn’t there, but because the financial infrastructure that has to support it all is broken.
The life sciences industry spends $300 billion a year on R&D. Today, most of that is trapped in spreadsheets, PDFs, and disconnected systems. That is the choke point. That is what’s standing between the world we have and the world we’re all trying to build.
Condor exists to remove that choke point. We give CFOs, clinical executives, and R&D leaders something the industry has never had: a living, breathing financial command center. The ability to see in real time where every dollar is going, how trials are performing, and where to reallocate and accelerate. It’s all made possible by our platform’s proprietary clinical and financial ontologies that map the relationships between trial protocols, site-level activity, vendor contracts, and accounting rules. The platform’s knowledge architecture was developed over years with Big 4 accounting firms and embedded in audit-grade workflows.
What gets me and everyone at Condor out of bed every morning is witnessing accounting, FP&A, and clinical operations teams have that “aha moment” when they turn on our platform. For example, the CFO of a growing biotech told us recently that for the first time she could see exactly where her clinical trial dollars were going. No spreadsheets stitched together late at night. No uncertainty heading into board meetings. Just a clear, trusted view of trial spend, forecasts, and risk. She told me, “For the first time, I feel like we’re making strategic and proactive decisions instead of explaining surprises.”
That shift from reactive to proactive is everything. Better visibility leads to better decisions. Better decisions drive better outcomes. And better outcomes mean more therapies reach the people who need them.
We aren’t building accounting software or a reporting tool. We’re building the infrastructure for how the industry funds innovation itself. Every drug discovered by AI, every molecule modeled, every trial run more efficiently — that future flows through financial infrastructure. Condor is building that infrastructure. This Series A gives us the resources to go further by expanding our platform, deepening our enterprise capabilities, and growing the extraordinary team that will carry this vision forward.
Read More – Standard Template Labs Raises $49M in Seed Funding
